28 Chapter 1 REFERENCES 1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211. 2. Peng K-P, May A. Redefining migraine phases – a suggestion based on clinical, physiological, and functional imaging evidence. Cephalalgia 2020;40:866-870. 3. Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 2016;139:1987-1993. 4. Martin VT, Wernke S, Mandell K, et al. Symptoms of Premenstrual Syndrome and Their Association With Migraine Headache. Headache: The Journal of Head and Face Pain 2006;46:125-137. 5. Peng KP, May A. Migraine understood as a sensory threshold disease. Pain 2019;160:14941501. 6. Van Casteren DS, Verhagen IE, De Boer I, et al. E-diary use in clinical headache practice: A prospective observational study. Cephalalgia 2021;41:1161-1171. 7. van Oosterhout WP, Weller CM, Stam AH, et al. Validation of the web-based LUMINA questionnaire for recruiting large cohorts of migraineurs. Cephalalgia 2011;31:1359-1367. 8. Verhagen IE, van der Arend BWH, van Casteren DS, le Cessie S, MaassenVanDenBrink A, Terwindt GM. Sex differences in migraine attack characteristics: A longitudinal E-diary study. Headache 2023;63:333-341. 9. Verhagen IE, Spaink HAJ, van der Arend BWH, van Casteren DS, MaassenVanDenBrink A, Terwindt GM. Validation of diagnostic ICHD-3 criteria for menstrual migraine. Cephalalgia 2022;42:1184-1193. 10. van Casteren DS, Verhagen IE, van der Arend BWH, van Zwet EW, MaassenVanDenBrink A, Terwindt GM. Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary. Neurology 2021;97:e1661-e1671. 11. Verhagen IE, de Vries Lentsch S, van der Arend BWH, le Cessie S, MaassenVanDenBrink A, Terwindt GM. Both perimenstrual and nonperimenstrual migraine days respond to anticalcitonin gene-related peptide (receptor) antibodies. Eur J Neurol 2023. 12. De Vries Lentsch S, Verhagen IE, Van Den Hoek TC, Maassenvandenbrink A, Terwindt GM. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. European Journal of Neurology 2021;28:4194-4203. 13. Nederland Z. GVS-advies CGRP-remmers erenumab, fremanezumab, galcanezumab (Aimovig, Emgality, AJOVY) bij de profylaxe van therapieresistente chronische migraine. 2021. 14. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort. Neurology 1999;53:537.
RkJQdWJsaXNoZXIy MjY0ODMw